奥替利单抗治疗类风湿关节炎的MRI与GM-CSF-CCL17轴评估:2a期随机机制研究
这项2a期随机双盲安慰剂对照研究评估了奥替利单抗对类风湿关节炎患者GM-CSF-CCL17轴和滑膜炎的影响,39例患者随机接受奥替利单抗180mg或安慰剂。奥替利单抗达到靶点结合但维持不佳,CCL17可能作为药效学标志物,滑膜炎有改善趋势但未达显著,耐受性良好。
要点
- 奥替利单抗每周给药达到靶点结合,但每两周给药未能维持。
- CCL17可能作为奥替利单抗活性的药效学生物标志物。
- 奥替利单抗耐受性良好,滑膜炎有改善趋势但未达统计学显著。
核心结论
- 血清GM-CSF-奥替利单抗复合物浓度表明初始每周给药达到靶点结合,但每两周给药未能维持。
- CCL17可能是未来研究中奥替利单抗活性的药效学生物标志物。
- 奥替利单抗耐受性良好,尽管暴露欠佳,在活动性类风湿关节炎患者中12周内显示滑膜炎改善的某些证据。
研究设计与样本
- 2a期随机双盲多中心安慰剂对照平行组研究,在美国、波兰和德国9个中心进行。
- 患者按3:1随机接受皮下奥替利单抗180 mg或安慰剂每周一次共5周,然后每两周一次至第10周(12周治疗期内),随后10周安全性随访。
- 随机化按早期类风湿关节炎(诊断≤2年)和 established 类风湿关节炎(诊断>2年)分层。
- 主要终点为112种生物标志物随时间的变化,次要终点为RAMRIS和RAMRIQ评估的滑膜炎、骨炎和侵蚀变化及安全性。
- 共39例患者随机分配并纳入分析(奥替利单抗n=28;安慰剂n=11)。
主要发现
- 与安慰剂相比,奥替利单抗在12周内未显著降低RAMRIS滑膜炎、骨炎和骨侵蚀或RAMRIQ滑膜炎和侵蚀损伤。
关键数值与推荐
- 患者符合美国风湿病学会-欧洲抗风湿病联盟2010年类风湿关节炎标准并接受稳定甲氨蝶呤治疗。
- 主要终点为112种生物标志物随时间变化,包括靶点结合标志物和可能指示疾病活动及应答的标志物。
- 次要终点为RAMRIS和RAMRIQ评估的滑膜炎、骨炎和侵蚀较基线变化及安全性。
- 生物标志物和MRI终点使用重复测量模型分析组间差异。
临床怎么用
- 奥替利单抗每周给药可达到靶点结合,但每两周给药暴露不足,需优化剂量方案。
- CCL17可作为奥替利单抗药效学标志物用于未来研究。
- 尽管暴露欠佳,奥替利单抗显示滑膜炎改善趋势,支持进一步研究。
局限性
- 样本量小(39例),可能影响统计效能。
- 每两周给药导致暴露欠佳,可能影响疗效评估。
- 研究为2a期机制研究,主要终点为生物标志物,非临床疗效终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Otilimab is a human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a driver in many immune-mediated inflammatory conditions. We evaluated the effect of otilimab on the GM-CSF-chemokine (C-C motif) ligand 17 (CCL17) axis and synovitis in patients with rheumatoid arthritis. METHODS: This phase 2a, randomised, double-blind, multicentre, placebo-controlled, parallel-group study was done at nine sites across the USA, Poland, and Germany. Patients aged 18 years or older with rheumatoid arthritis per American College of Rheumatology-European League Against Rheumatism 2010 criteria and receiving stable methotrexate were randomly assigned (3:1) by an interactive response technology system to either subcutaneous otilimab 180 mg or placebo once weekly for 5 weeks, then every other week until week 10 (within a 12-week treatment period), followed by a 10-week safety follow-up. Randomisation was stratified by early rheumatoid arthritis (≤2 years since diagnosis) and established rheumatoid arthritis (>2 years since diagnosis). Patients and study personnel (except for an unblinded coordinator or nurse who prepared and administered the study drug) were blinded to treatment assignment; the syringe was shielded during administration. Patients were enrolled by study investigators and allocated to a treatment by central randomisation on the basis of a schedule generated by the sponsor. The primary endpoint was change over time (assessed at baseline and weeks 1, 2, 4, 6, 8, 12, and 22 of follow-up) in 112 biomarkers, including target engagement biomarkers and those that may be indicative of rheumatoid arthritis disease activity and response to otilimab. Secondary endpoints were change from baseline in synovitis, osteitis and erosion assessed by rheumatoid arthritis MRI scoring system (RAMRIS) and rheumatoid arthritis MRI quantitative score (RAMRIQ), and safety evaluation. The primary, secondary, and safety endpoints were assessed in the intention-to-treat population. Biomarker and MRI endpoints were analysed for differences between treatment groups using a repeated measures model. This study is registered with ClinicalTrials.gov, NCT02799472. FINDINGS: Between Aug 9, 2016, and Oct 30, 2017, 39 patients were randomly assigned and included in the analysis (otilimab n=28; placebo n=11). In the otilimab group, mean serum concentrations of GM-CSF-otilimab complex peaked at week 4 (138·4 ng/L, 95% CI 90·0-212·9) but decreased from week 6-12. CCL17 concentrations decreased from baseline to week 1, remained stable to week 8, and returned to baseline at week 12; least-squares mean ratio to baseline was 0·65 (95% CI 0·49-0·86; coefficient of variation 13·60) at week 2, 0·68 (0·53-0·88; 12·51) at week 4, 0·78 (0·60-1·00; 12·48) at week 6, and 0·68 (0·54-0·85; 11·21) at week 8. No meaningful change in CCL17 concentrations was observed with placebo. In the otilimab group, the least-squares mean ratio to baseline in MMP-degraded type I collagen was 0·86-0·91 over weeks 1-8, returning to baseline at week 12; concentrations remained above baseline at all timepoints in the placebo group. There were no observable differences between otilimab and placebo for all other biomarkers. At week 12, least-squares mean change in RAMRIS synovitis score from baseline was -1·3 (standard error [SE] 0·6) in the otilimab group and 0·8 (1·2) with placebo; RAMRIQ synovitis score showed a least-squares mean change from baseline of -1417·0 μl (671·5) in the otilimab group and -912·3 μl (1405·8) with placebo. Compared with placebo, otilimab did not show significant reductions from baseline to week 12 in RAMRIS synovitis, osteitis and bone erosion, or in RAMRIQ synovitis and erosion damage. Adverse events were reported in 11 (39%) of 28 otilimab-treated and four (36%) of 11 placebo-treated patients, most commonly cough in the otilimab group (2 [7%] of 28; not reported in placebo group), and pain in extremity (four [36%] of 11) and rheumatoid arthritis (two [18%] of 11) in the placebo group (not reported in otilimab group). There were no serious adverse events or deaths. INTERPRETATION: Serum concentrations of GM-CSF-otilimab complex indicated that target engagement was achieved with initial weekly dosing, but not sustained with every other week dosing. CCL17 might be a pharmacodynamic biomarker for otilimab activity in future studies. Otilimab was well tolerated and, despite suboptimal exposure, showed some evidence for improved synovitis over 12 weeks in patients with active rheumatoid arthritis. FUNDING: GlaxoSmithKline.
引用
- Genovese MC, Berkowitz M, Conaghan PG, et al. MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatol. 2020. PMID: 38279363. doi:10.1016/S2665-9913(20)30224-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。